What is Directed Genomics?
Directed Genomics is dedicated to the creation of innovative DNA and RNA preparation technologies aimed at enhancing the precision and throughput of genomic interrogation. Their core technology offers a groundbreaking approach to target enrichment for next-generation sequencing, effectively combining the advantages of traditional hybridization- and PCR-based methodologies. This results in an easily automated, six-hour target enrichment workflow that demonstrates exceptional specificity and uniformity, capable of scaling from single-gene analysis to comprehensive multi-gene panels.
How much funding has Directed Genomics raised?
Directed Genomics has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Directed Genomics
PPP
Public-Private Partnership
What's next for Directed Genomics?
With a substantial capital infusion, Directed Genomics is poised for accelerated growth and market expansion. The company's focus on streamlining genomic analysis through its proprietary target enrichment technology positions it to address critical needs in both the research and clinical diagnostics sectors. Future strategic initiatives will likely involve scaling production, expanding its commercial reach, and potentially forging new partnerships to integrate its solutions into broader genomic workflows, further solidifying its role in the evolving landscape of precision medicine.
See full Directed Genomics company page
